Stockscreener 앱 받기
104.88
1.14%
1.18
시간 외 거래:
104.84
-0.04
-0.04%
전일 마감가:
$103.70
열려 있는:
$103.01
하루 거래량:
7.83M
Relative Volume:
0.70
시가총액:
$181.48B
수익:
$46.59B
순이익/손실:
$5.41B
주가수익비율:
33.90
EPS:
3.0938
순현금흐름:
$7.38B
1주 성능:
+0.79%
1개월 성능:
+3.54%
6개월 성능:
+15.09%
1년 성능:
-17.32%
1일 변동 폭
$102.90
$105.24
1주일 범위
$97.67
$106.35
52주 변동 폭
$81.97
$132.03
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs MDT, SYK, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
104.88 | 181.48B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.79 | 121.25B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
306.13 | 117.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
45.58 | 66.06B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.56 | 52.20B | 6.30B | 1.07B | 1.09B | 1.8406 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-07 | 개시 | Barclays | Overweight |
| 2026-10-02 | 업그레이드 | Rothschild & Co Redburn | Neutral → Buy |
| 2026-08-13 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2026-07-01 | 개시 | Robert W. Baird | Outperform |
| 2026-04-22 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Abbott Laboratories vs. UnitedHealth: Does Health Innovation or Health Insurance Make for a Better Stock to Buy? - The Motley Fool
Catheter Precision Announces Publication of Comparative Study Showing LockeT Outperforms Abbott’s Perclose Internal Vascular Closure Device - GlobeNewswire Inc.
Abbott: 3 Key Takeaways for Long-Term Investors - The Motley Fool
Pre-Markets in Green on Strong Earnings Results - Zacks Investment Research
Pre-Markets Up on Cooling Metrics, Decent Q3 Reports - Zacks Investment Research
Abbott (ABT) Misses Q3 Earnings Estimates - Zacks Investment Research
Global Digital Health and Remote Patient Monitoring Strategic Market Report, 2026-2031 | 20.2% CAGR to $80.8 Billion as Connected Care and Wearables Scale - GlobeNewswire Inc.
Abbott Laboratories (ABT) Secures Europe CE Mark For Colorectal Cancer Test - Yahoo Finance
Abbott Laboratories Earnings Ahead: What Past Reactions Say About The Stock - Trefis
Abbott (ABT): Can Libre Keep Growing as Glucose Monitoring Becomes More Competitive? - Yahoo Finance
Kevin Warsh's Fed May Not Cut Rates Soon. That's Why This Dividend Stock Belongs in Your Portfolio. - The Motley Fool
Abbott Q3 preview: What to expect (ABT:NYSE) - Seeking Alpha
The Zacks Analyst Blog Highlights Abbott Laboratories, Johnson & Johnson, Stryker, Waste Management and Republic Services - The Globe and Mail
DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study - Zacks Investment Research
How To Earn $500 A Month From Abbott Stock Ahead Of Q3 Earnings - Benzinga
What iShares U.S. Medical Devices ETF (IHI) Sold: Abbott Leads on Friday - Yahoo Finance
Abbott schedules results. Abbott Laboratories stock trades 17.78 percent below its yearly high - ad-hoc-news.de
Key facts: Abbott Laboratories to Report Q3; Cologuard Plus CE Mark - TradingView
Abbott Wins Bid To Move Ex-Worker's Bias Suit To Illinois - Law360
2 Industries Beyond AI With Long-Term Demand Drivers for 2027 - Zacks Investment Research
UBS reiterates Buy on Abbott Labs stock, cites biosimilars pipeline - Investing.com
UBS reiterates Buy on Abbott Labs stock, cites biosimilars pipeline By Investing.com - Investing.com India
3 Wall Street Analysts See Intuitive Surgical Hitting $500. Here's the Bull Case. - The Motley Fool
Alert incorrectly tagged to Abbott Laboratories withdrawn - marketscreener.com
Abbott Laboratories expected to post earnings of $1.42 a shareEarnings Preview - TradingView
Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q3 Earnings - Benzinga
Abbott Laboratories stock at EUR 93.23 ahead of the Xetra open - ad-hoc-news.de
Ken Griffin Increased His Position in This Dividend King by a Whopping 546% in Q2. Here's Why It's Still a Buy. - The Motley Fool
Is Abbott Laboratories (ABT) Undervalued Following Product Launches And Growth Expectations? - Simply Wall Street
Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle - The Motley Fool
StoneX reiterates Buy on Abbott Labs stock ahead of earnings By Investing.com - Investing.com India
StoneX reiterates Buy on Abbott Labs stock ahead of earnings - Investing.com
Abbott Laboratories stock: TD Cowen sets a USD 135.00 target for Abbott Laboratories stock - ad-hoc-news.de
TD Cowen on Abbott Labs (ABT): 'The Stage is Set for a Stronger 2H' - StreetInsider
Reasons to Add STE Stock to Your Portfolio Right Now - Zacks Investment Research
Haemonetics Gains 149.3% in a Year: What's Driving the Rally? - Zacks Investment Research
Is it Apt to Retain Medtronic Stock in Your Portfolio Now? - Zacks Investment Research
Pregnancy Tests Recalled Globally Over False Positives - Gizmodo
Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now? - Zacks Investment Research
Abbott Laboratories To Go Ex-Dividend On October 15th, 2026 With 0.63 USD Dividend Per Share - Moomoo
Abbott Laboratories stock may move 4.7% on earnings release - Investing.com
Global Microbiology Testing Market to Grow Rapidly at a CAGR of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.
Why Did J&J Stock Fall After Q3 Earnings Despite Raised Guidance? - Zacks Investment Research
Medtronic Pays More Today. Abbott Raises Its Dividend Faster. Which Stock Wins? - 24/7 Wall St.
Abbott Laboratories (ABT) Is A Key Player In Closed Loop Neurostimulation - Yahoo Finance
SimpleScreen CRC Launch Could Be A Big Moment For Abbott Stock - Simply Wall Street
Should You Add Abbott Stock to Your Portfolio Ahead of Q3 Earnings? - TradingView
Should You Add Abbott Stock to Your Portfolio Ahead of Q3 Earnings? - Yahoo Finance
Want Passive Income for Life? Here Are 2 Dividend Stocks to Buy and Never Sell - The Motley Fool
Abbott (ABT) Gains As Market Dips: What You Should Know - Zacks Investment Research
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
애보트 래버러토리스 주식 (ABT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| John A. McCoy, Jr. | Officer |
Sep 02 '26 |
Proposed Sale |
109.52 |
27 |
2,957 |
0 |
| Robert B. Ford | Officer |
Aug 25 '26 |
Proposed Sale |
115.85 |
398,832 |
46,204,386 |
0 |
| Ford Robert B | CHAIRMAN AND CEO |
Aug 25 '26 |
Sale |
115.85 |
398,832 |
46,204,798 |
306,461 |
| Ford Robert B | CHAIRMAN AND CEO |
Aug 25 '26 |
Option Exercise |
54.02 |
398,832 |
21,545,946 |
705,293 |
| Morrone Louis H. | EXECUTIVE VICE PRESIDENT |
Aug 11 '26 |
Sale |
109.83 |
5,850 |
642,506 |
70,724 |
| Louis H. Morrone | Officer |
Aug 11 '26 |
Proposed Sale |
109.83 |
5,850 |
642,506 |
0 |
| Robert J. Alpern | Retired Director |
May 15 '26 |
Proposed Sale |
85.25 |
7,587 |
646,791 |
0 |
| Stratton John G | Director |
May 07 '26 |
Buy |
86.82 |
2,000 |
173,640 |
23,319 |
| STARKS DANIEL J | Director |
Apr 27 '26 |
Buy |
92.65 |
10,000 |
926,537 |
6,751,103 |
| Robert J. Alpern | Retired Director |
Apr 27 '26 |
Proposed Sale |
92.55 |
29,211 |
2,703,457 |
0 |
0.65%
1.67%
자본화:
|
볼륨(24시간):